Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2010

Nov 10, 2010

30291_dirs_2010-11-10_91bc541c-8463-4c4d-a5b1-ff49f5fc61cf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2010-11-09

Reporting Person: Cox John (EVP Pharmaceutical Oper & Tech)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2010-11-09 Common Stock S 773 $62.868 Disposed 16356.0411 Direct

Footnotes

F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: This represents the weighted average price for shares sold at a range between $62.72 (low) and 62.95 (high).

F3: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.